Clinical perspectives on the value of testing for <i>STK11</i> and <i>KEAP1</i> mutations in advanced NSCLC.

ABSTRACT: Standard first-line therapy for patients with metastatic non-small cell lung cancer (mNSCLC) without identified actionable mutations consists of regimens comprising immune checkpoint inhibitors (ICIs), alone or in combination with platinum-based chemotherapy (CTx). However, approximately 20-30% of patients with mNSCLC (including some patients with high tumor programmed cell death ligand-1 expression) display primary resistance to ICIs, either alone or in combination with CTx. Mutations in tumor suppressor genes serine/threonine kinase 11 (STK11), and Kelch-like ECH-associated protein 1 (KEAP1) often detected in patients with Kirsten rat sarcoma virus mutations, are associated with an aggressive disease phenotype and resistance to standard ICI regimens. Co

SUBMITTER: Shiller M 

PROVIDER: S-EPMC11655323 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature